{"url_path":"/sec/aidx/8-k/2026-07-22/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-22","source_url":"https://www.sec.gov/Archives/edgar/data/1139685/0001213900-26-080432-index.html","accession_number":"0001213900-26-080432","cik":"0001139685","ticker":"AIDX","issuer_name":"20/20 Biolabs, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1139685/0001213900-26-080432-index.html","primary_entity_key":"0001139685","primary_entity_name":"20/20 Biolabs, Inc."},"word_count":90,"has_tables":true,"body_markdown":"** **\n\n**Item\n9.01 Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit No.**\n \n**Description of Exhibit**\n\n10.1\n \n[Standstill Agreement, dated July 16, 2026, between Streeterville Capital, LLC and 20/20 Biolabs, Inc.](ea029890701ex10-1.htm)\n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n1\n\n**  **\n\n**SIGNATURES**\n\n** **\n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\nDate: July 22, 2026\n20/20 BIOLABS, INC.\n\n \n \n\n \n/s/ Jonathan Cohen\n\n \nName:\nJonathan Cohen\n\n \nTitle:\nChief Executive Officer\n\n  \n\n2"}